S&P Futures
3,274.00-28.25(-0.86%)Dow Futures
26,390.00-167.00(-0.63%)Nasdaq Futures
11,197.50-145.25(-1.28%)
OptimizeRx Corporation (OPRX)
20.17 0.00 (0.00%)
After hours: 4:04PM EDT
Chart Events
Performance Outlook
| Previous Close | 20.03 |
| Open | 20.16 |
| Bid | 18.50 x 1000 |
| Ask | 20.18 x 800 |
| Day's Range | 19.52 - 21.10 |
| 52 Week Range | 6.50 - 22.55 |
| Volume | 67,726 |
| Avg. Volume | 173,266 |
| Market Cap | 303.417M |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.47 |
| Earnings Date | Nov 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.33 |
- Simply Wall St.
OptimizeRx (NASDAQ:OPRX) Shareholders Have Enjoyed A Whopping 463% Share Price Gain
For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a...
- GlobeNewswire
OptimizeRx Sets Third Quarter 2020 Conference Call for Monday, November 9, 2020 at 4:30 p.m. ET
ROCHESTER, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Monday, November 9, 2020 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2020. OptimizeRx management will host the call, followed by a question and answer period. As earlier reported, the company expects to report record revenue for the quarter of more than $10.0 million, up over 100% from the same year-ago quarter, along with positive non-GAAP net income.On the call, management will review how this growth has been driven organically by a combination of enterprise deals and tactical programs, as the company’s life science customers increasingly see the value in transparent access to physicians and patients provided by the OptimizeRx Digital Health Platform.The full financial results for the quarter will be issued in a press release prior to the call.Conference Call Information Date: Monday, November 9, 2020 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Toll-free dial-in number: 1-800-430-8332 International dial-in number: 1-323-347-3277 Conference ID: 9818386Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.A replay of the call will be available after 7:30 p.m. Eastern time on the same day through November 30, 2020, as well as available for replay via the Investors section of the OptimizeRx website at www.optimizerx.com/investors.Toll-free replay number: 1-844-512-2921 International replay number: 1-412-317-6671 Replay ID: 9818386About OptimizeRx OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.OptimizeRx Contact Doug Baker, CFO Tel (248) 651-6568 (x807) dbaker@optimizerx.com Media Contact Maira Alejandra, Media Relations Manager Tel (754) 245-7070 malejandra@optimizerx.comInvestor Relations Contact Ron Both, CMA Tel (949) 432-7557 oprx@cma.team
- GlobeNewswire
OptimizeRx to Participate at Investor Conferences in November
ROCHESTER, Mich., Oct. 20, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to participate in two investor conferences being held in November. Event: ROTH Technology Virtual Conference Attendance Date: November 11, 2020 Format: Virtual 1x1 and small group meetings Registration: Email registration@roth.com or click here.Event: Stifel Midwest One-on-One Growth Conference Attendance Date: November 12, 2020 Format: Virtual 1x1 meetings Registration: Please contact your Stifel institutional sales representative.OptimizeRx management is scheduled to participate in virtual one-on-one meetings with institutional investors and analysts at both conferences.Management will discuss the company’s recently reported preliminary results for the third quarter of 2020. The company expects record revenue of more than $10.0 million, up over 100% versus the same year-ago quarter, along with positive non-GAAP net income.They will review how this growth is being driven organically by a combination of enterprise deals and tactical programs, as its life science customers increasingly see the value in transparent access to physicians and patients via the OptimizeRx digital health platform.To schedule a virtual one-on-one meeting with OptimizeRx, you may submit your request via the links provided upon your registration for the conferences. For any questions about the company, please contact Ron Both of CMA at (949) 432-7557 or submit your request here.About Roth Capital Partners ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.About Stifel Stifel is a full-service investment firm with a distinguished history of providing securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, institutions, corporations, and municipalities. Established in 1890 and headquartered in St. Louis, Missouri, Stifel is one of the nation’s leading firms.For more information about Stifel, visit www.stifel.com.About OptimizeRx OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.OptimizeRx Contact Doug Baker, CFO Tel (248) 651-6568 (x807) dbaker@optimizerx.com Media Relations Contact Maira Alejandra, Media Relations Manager Tel (754) 245-7070 malejandra@optimizerx.comInvestor Relations Contact Ron Both, CMA Tel (949) 432-7557 oprx@cma.team
